VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C

被引：0
|
作者：
Hammond, E. [1 ]
Lucas, A. [1 ]
Lucas, M. [1 ]
Phillips, E. [1 ,4 ,5 ]
Gaudieri, S. [2 ,3 ,6 ,7 ]
机构：
[1] Murdoch Univ, Inst Immunol & Infect Dis, Ctr Clin Immunol & Biomed Stat, Murdoch, WA 6150, Australia
[2] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia
[3] Royal Perth Hosp, Perth, WA, Australia
[4] Univ Western Australia, Sch Pathol, Nedlands, WA 6009, Australia
[5] Univ Western Australia, Lab Med & Biomed Biomol & Chem Sci, Nedlands, WA 6009, Australia
[6] Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia
[7] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia
来源：
DRUGS OF THE FUTURE | 2010年 / 35卷 / 10期
关键词：
MK-7009; CHRONIC HEPATITIS-C; VIRUS NS3/4A PROTEASE; PEGINTERFERON ALPHA-2A; RIBAVIRIN THERAPY; RESISTANCE; INHIBITORS; TELAPREVIR; NOMENCLATURE; ASSOCIATION; MANAGEMENT;
D O I：
10.1358/dof.2010.035.010.1527293
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protease inhibitors are among a number of new classes of direct-acting antivirals for hepatitis C which, when combined with conventional peginterferon alfa/ribavirin or with other classes of direct-acting antivirals, offer the potential to vastly improve disease outcomes for affected individuals. Early evaluations imply that a number of these agents are well tolerated and produce encouraging rapid declines in plasma viral load. Concerns relate to the rapid development of drug resistance, with resulting viral rebound. Vaniprevir (MK-7009) is a novel inhibitor of genotype 1 proteases with some potency against genotype 2 currently undergoing phase II trials.
引用
收藏
页码：803 / 813
页数：11
相关论文
共 50 条
  • [21] Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir
    Susser, Simone
    Flinders, Mathieu
    Reesink, Henk W.
    Zeuzem, Stefan
    Lawyer, Glenn
    Ghys, Anne
    Van Eygen, Veerle
    Witek, James
    De Meyer, Sandra
    Sarrazin, Christoph
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (05) : 2746 - 2755
  • [22] Chronic Hepatitis C Treatment Failure with current NS3/4A protease inhibitors
    Mousa, Omar
    Kim, Chang H.
    Pham, Ly-Elaine
    Egwim, Chukwuma I.
    Zela, Scott A.
    Ankoma-Sey, Victor
    HEPATOLOGY, 2013, 58 : 1307A - 1308A
  • [23] Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection
    Mederacke, Ingmar
    Wedemeyer, Heiner
    Manns, Michael P.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (02) : 181 - 189
  • [24] Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
    Moucari, Rami
    Forestier, Nicole
    Larrey, Dominique
    Guyader, Dominique
    Couzigou, Patrice
    Benhamou, Yves
    Voitot, Helene
    Vidaud, Michel
    Seiwert, Scott
    Bradford, Bill
    Zeuzem, Stefan
    Marcellin, Patrick
    GUT, 2010, 59 (12) : 1694 - 1698
  • [25] Discovery of vaniprevir (MK-7009) and MK-5172: Macrocyclic HCV NS3/4a protease inhibitors
    Rudd, Michael T.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [26] Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir
    Berger, Kristi L.
    Triki, Ibtissem
    Cartier, Mireille
    Marquis, Martin
    Massariol, Marie-Josee
    Boecher, Wulf O.
    Datsenko, Yakov
    Steinmann, Gerhard
    Scherer, Joseph
    Stern, Jerry O.
    Kukolj, George
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 698 - 705
  • [27] Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
    Venkatraman, Srikanth
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 289 - 294
  • [28] Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease
    Sheng, X. Christopher
    Appleby, Todd
    Butler, Thomas
    Cai, Ruby
    Chen, Xiaowu
    Cho, Aesop
    Clarke, Michael O.
    Cottell, Jeromy
    Delaney, William E.
    Doerffler, Edward
    Link, John
    Ji, Mingzhe
    Pakdaman, Rowchanak
    Pyun, Hyung-Jung
    Wu, Qiaoyin
    Xu, Jie
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) : 2629 - 2634
  • [29] Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
    Harper, Steven
    McCauley, John A.
    Rudd, Michael T.
    Ferrara, Marco
    DiFilippo, Marcello
    Crescenzi, Benedetta
    Koch, Uwe
    Petrocchi, Alessia
    Holloway, M. Katharine
    Butcher, John W.
    Romano, Joseph J.
    Bush, Kimberly J.
    Gilbert, Kevin F.
    McIntyre, Charles J.
    Nguyen, Kevin T.
    Nizi, Emanuela
    Carroll, Steven S.
    Ludmerer, Steven W.
    Burlein, Christine
    DiMuzio, Jillian M.
    Graham, Donald J.
    McHale, Carolyn M.
    Stahlhut, Mark W.
    Olsen, David B.
    Monteagudo, Edith
    Cianetti, Simona
    Giuliano, Claudio
    Pucci, Vincenzo
    Trainor, Nicole
    Fandozzi, Christine M.
    Rowley, Michael
    Coleman, Paul J.
    Vacca, Joseph P.
    Summa, Vincenzo
    Liverton, Nigel J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (04): : 332 - 336
  • [30] MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
    Liverton, Nigel J.
    Carroll, Steven S.
    DiMuzio, Jillian
    Fandozzi, Christine
    Graham, Donald J.
    Hazuda, Daria
    Holloway, M. Katherine
    Ludmerer, Steven W.
    McCauley, John A.
    McIntyre, Charles J.
    Olsen, David B.
    Rudd, Michael T.
    Stahlhut, Mark
    Vacca, Joseph P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 305 - 311
12345